Lead-up to Novo Nordisk report: Growth-heavy quarter with GLP-1 focus ahead

Thursday's quarterly report from Novo Nordisk will emphasize the pharmaceutical company's diabetes 2 treatments Ozempic and Rybelsus, as well the new weight-loss drug Wegovy, which is in high demand.
Photo: Jacob Gronholt-Pedersen/Reuters/Ritzau Scanpix
Photo: Jacob Gronholt-Pedersen/Reuters/Ritzau Scanpix

Novo Nordisk is looking into a growth-heavy Q2, as it has had tailwind with diabetes 2 drugs Ozempic and Rybelsus, and as the demand is high for its new weight-loss treatment Wegovy.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading